<DOC>
	<DOCNO>NCT01128686</DOCNO>
	<brief_summary>This evaluate proportion subject show good response LAM treatment Korea .</brief_summary>
	<brief_title>Lamivudine ( LAM ) Good Responder Study</brief_title>
	<detailed_description>This evaluate proportion subject show good response LAM treatment HBV DNA negativity , HBV DNA le 4 log , resistant mutation , HBeAg seroconversion normalization ALT naïve CHB patient certain pre-treatment characteristic , i.e . HBV DNA le 9log copy per ml ALT 2 time ULN HBeAg positive subject , HBV DNA le 7log copy per ml elevate ALT HBeAg negative subject .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<criteria>1 . CHB liver cirrhosis due Hepatitis B virus start LAM Jan 1 , 2003 Dec 31 , 2004 maintain LAM least 6 month 2 . HBsAg positive least 6 month begin observation 3 . HBV DNA positive LAM administration 4 . Subjects certain pretreatment laboratory finding follow ; HBV DNA le 9log copy per ml ALT 2 time ULN HBeAg positive patient , HBV DNA le 7log copy per ml elevate ALT HBeAg negative patient 1 . Documented coinfection HCV , HIV begin LAM treatment 2 . Decompensated liver cirrhosis begin LAM treatment 3 . HCC begin LAM treatment</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>retrospective</keyword>
	<keyword>naïve Chronic Hepatitis B ( CHB ) patient</keyword>
	<keyword>cohort study</keyword>
	<keyword>lamivudine</keyword>
</DOC>